Claritas Genomics announces start of Claritas Clinical Exome.

If medical presentations are clear, the coverage and accuracy of the Claritas Clinical Exome gives healthcare providers the choice to choose focused Regions of Interest lab tests from a set of pre-defined gene lists, thereby replacing lengthy and costly sequential gene panel testing. Today cover pediatric neurology The first gene sets available, which targets conditions including neuromuscular disorders, epilepsy and seizures. Claritas will start other tests this year later. This integrated solution offers a complete range of sophisticated however intuitive interpretation and data visualization tools, making it possible to determine causal variants in a higher proportion of cases than panels alone, thus providing healthcare providers and a much better number of individuals with critical information and tips for guiding treatment and treatment.A fresh study released in the January 2013 issue of the International Association for the Study of Lung Cancer's Journal of Thoracic Oncology, concludes the new IASLC/ATS/ERS classification identifies histologic subtypes of lung adenocarcinomas with prognostic value among Japanese individuals. Related StoriesNew RNA check of blood platelets can be used to identify location of cancerCrucial transformation in single DNA base predisposes children to intense form of cancerStudy shows uncommon HER2 missense mutations do not spread breasts cancer on their own Researchers looked at individuals with lung adenocarcinoma who underwent pul-monary resection between January 2001 and December 2009 at Kyoto University Hospital, Japan.